Targeting Kras: Pros and Cons of In Vitro Tools Versus Mouse Models

Time: 3:30 pm
day: Day One


  • Can genetic models discriminate between tumour initiating and tumour maintaining effects of KRAS?
  • Can we improve the identification of biomarkers for better treatment options?
  • Can genetic models be used to predict the toxicity of new KRAS-specific drugs?